Alpaca Enters UK and EU Market through WealthKernel Acquisition
Alpaca, a self-clearing broker-dealer and brokerage infrastructure API, today announced its intended acquisition of WealthKernel, a wealthtech firm specializing in digital investment infrastructure and tax-advantaged products. This strategic acquisition will bring WealthKernel’s UK and EU licensed brokerage infrastructure to Alpaca, supporting their rapid global expansion to achieve its mission of opening financial services to everyone on the planet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710149866/en/
Alpaca, a self-clearing broker-dealer and brokerage infrastructure API, today announced its intended acquisition of WealthKernel, a wealthtech firm specializing in digital investment infrastructure and tax-advantaged products. "The acquisition of WealthKernel is a major step for Alpaca in becoming a truly global brokerage infrastructure. WealthKernel has gained a highly regarded reputation in the UK and EU through working closely with a number of financial institutions," said Yoshi Yokokawa, CEO of Alpaca. "With WealthKernel joining us, we’re directly entering the UK and EU, enhancing our support of global institutions that desire regulated investing across borders."
“The acquisition of WealthKernel is a major step for Alpaca in becoming a truly global brokerage infrastructure. WealthKernel has gained a highly regarded reputation in the UK and EU through working closely with a number of financial institutions,” said Yoshi Yokokawa, CEO of Alpaca. “With WealthKernel joining us, we’re directly entering the UK and EU, enhancing our support of global institutions that desire regulated investing across borders.”
WealthKernel brings wealth management capabilities, including ISAs, SIPPs, and other tax-advantaged accounts, complementing Alpaca’s trading infrastructure. Alpaca, which has long supported their UK and EU partners, now gains the ability to act as a fully authorized broker-dealer through WealthKernel’s licenses.
“Joining forces with Alpaca will allow us to scale our mission faster, while maintaining the high standards our clients expect,” said Karan Shanmugarajah, CEO of WealthKernel. “We’re excited to bring our regulatory expertise and deep product set to Alpaca’s global platform.”
The deal unites a strong team with deep expertise in brokerage operations, compliance, and financial technology—leveraging shared tech and compliance frameworks. Further strengthening this foundation, Alpaca’s recently appointed CFO, Nadia Asoyan, brings seasoned fintech leadership from prior executive roles at Robinhood and Square. The combined organization will continue global operations, with key hubs in North America, Europe, and Asia.
This intended acquisition reinforces Alpaca’s position as a full-stack, global brokerage infrastructure provider, enabling brokers, banks, and fintechs to launch trading, custody, and wealth products quickly, compliantly, and at scale. Earlier this year, Kraken strategically partnered with Alpaca to deliver commission-free US equities trading to their US clients and joined as one of their 200+ global partners.
Regulatory Disclosures
Completion of the acquisition remains subject to regulatory approval from the UK Financial Conduct Authority and the Spanish Comisión Nacional del Mercado de Valores.
About Alpaca
Alpaca is a US-headquartered self-clearing broker-dealer and brokerage infrastructure for stocks, ETFs, options, crypto, fixed income, and 24/5 trading – raising over USD170 million in funding. Alpaca is backed by top-tier investors globally, including Portage Ventures, Spark Capital, Tribe Capital, Social Leverage, Horizons Ventures, Unbound, SBI Group, Derayah Financial, Elefund, and Y Combinator.
About WealthKernel
WealthKernel provides investment and savings infrastructure for regulated businesses in the UK and EU. With a focus on modern wealth products, compliance, and developer-first technology, WealthKernel enables firms to build and scale digital investment experiences.
Options trading is not suitable for all investors due to its inherent high risk, which can potentially result in significant losses. Please read Characteristics and Risks of Standardized Options before investing. All investments involve risk; for more information, please see our Disclosure Library. Brokerage services are provided by Alpaca Securities LLC (member FINRA/SIPC), a subsidiary of AlpacaDB, Inc. Crypto services are provided by Alpaca Crypto LLC, a FinCEN-registered MSB (NMLS #2160858) and AlpacaDB subsidiary; it is not a SIPC or FINRA member, crypto assets are not FDIC or SIPC insured. Technology and Services offered by AlpacaDB, Inc. This is not an offer, solicitation, or advice to buy, sell, or open accounts in any jurisdiction where Alpaca is unlicensed.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710149866/en/
Contacts
Media Contact
Patrick Valoppi
press@alpaca.markets
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom